Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

NCT03266783 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.

NCT NCT03266783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03266783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Lead sponsor
Ottawa Hospital Research Institute
Phase
Phase 4
Overall status
Completed
Start date
December 13, 2017
Completion date
October 15, 2025
Enrollment
2,760 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

venous thromboembolism